KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Edwards Lifesciences (EW) EBT (2016 - 2025)

Edwards Lifesciences has reported EBT over the past 17 years, most recently at $90.4 million for Q4 2025.

  • Quarterly results put EBT at $90.4 million for Q4 2025, down 76.83% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (down 17.78% YoY), and the annual figure for FY2025 was $1.3 billion, down 17.78%.
  • EBT for Q4 2025 was $90.4 million at Edwards Lifesciences, down from $348.4 million in the prior quarter.
  • Over the last five years, EBT for EW hit a ceiling of $545.5 million in Q2 2021 and a floor of $90.4 million in Q4 2025.
  • Median EBT over the past 5 years was $389.7 million (2021), compared with a mean of $373.6 million.
  • Biggest five-year swings in EBT: soared 424.32% in 2021 and later crashed 76.83% in 2025.
  • Edwards Lifesciences' EBT stood at $376.3 million in 2021, then crashed by 43.82% to $211.4 million in 2022, then skyrocketed by 73.7% to $367.2 million in 2023, then rose by 6.24% to $390.1 million in 2024, then crashed by 76.83% to $90.4 million in 2025.
  • The last three reported values for EBT were $90.4 million (Q4 2025), $348.4 million (Q3 2025), and $400.2 million (Q2 2025) per Business Quant data.